GlassScriptPhysician profile
Jenica Marks
NPI 1699915900
$1,372.76
in general payments reported to CMS, 2019-2025
17 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $46.91 · 2022: $59.84 · 2023: $178 · 2024: $35.00 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.02 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $246.83 | 2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $235.79 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Astellas Pharma US INC | $136.76 | 2022-2023 | Veozah |
| Abbvie INC. | $119.56 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.11 | 2021-2025 | Caplyta |
| Alkermes, INC. | $97.56 | 2025 | Aristada, Lybalvi |
| Lundbeck LLC | $77.33 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $69.19 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $58.36 | 2025 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $51.01 | 2025 | Cobenfy |
| Sumitomo Pharma America, INC. | $39.41 | 2023 | Gemtesa |
| Supernus Pharmaceuticals, INC. | $33.28 | 2025 | Qelbree |
| Myovant Sciences INC. | $24.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.19 | 2025 | Trintellix |
| Boston Scientific Corporation | $20.82 | 2023 | Upsylon |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $16.10 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.06 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenica Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.